Acute Cardioversion versus Wait And See-approach for symptomatic atrial fibrillation in the emergency department (ACWAS-trial)

Acute Cardioversion versus Wait And See-approach for symptomatic atrial fibrillation in the emergency department (ACWAS-trial) - ACWAS-trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON47614

Enrollment

437

Registered

2014-08-04

Start date

2014-10-06

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation irregular heartbeat

Interventions

The intervention consists of a wait-and-see approach (WASA) with symptom reduction. A visit within 48 hours after onset of symptoms will be planned to check for conversion to SR. If AF is still pres

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • ECG with atrial fibrillation at the emergency department, recorded by General Practicioner or recorded in Ambulance • Heart rate > 70bpm • Symptoms most probable due to atrial fibrillation • Duration of symptoms 18 years of age • Able and willing to sign informed consent • Able and willing to use MyDianostick

Exclusion criteria

Exclusion criteria: Signs of myocardial infarction on ECG Hemodynamic instability (systolic blood pressure 170 bpm) Presence of pre-excitation syndrome History of Sick Sinus Syndrome History of unexplained syncope History of persistent AF (episode of AF lasting more than 48 hours) Acute heart failure Currently enrolled in another clinical trial Deemed unsuitable for paticipation by attending physician

Design outcomes

Primary

Measure	Time frame
Sinus rhythm (SR) at 1 month after inclusion	—

Secondary

Measure	Time frame
-AF-burden (MyDiagnostick) -Hospitalization for stroke/TIA, emboli, bleeding, myocardial infarction, PCI/CABG, arrhythmia -All cause mortality -Biomarkers (safety and predictors of conversion/maintenance of SR) -QoL -Cost-effectiveness	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)